EGFR and non-small cell lung carcinoma: From the perspective of the United States health care system, first‐line osimertinib plus chemotherapy is not cost‐effective compared with osimertinib monotherapy for patients with EGFR‐mutated (Ex19del or L858R mutations) advanced NSCLC.